Amgen reported a 10% increase in total revenues to $10.1 billion for Q2 2026, driven by a 9% growth in product sales and volume gains across 22 products. GAAP EPS surged 65% to $4.37, supported by higher revenues and improved operating margins. The company highlighted strong growth in key products like Repatha and EVENITY, ongoing Phase 3 trials for new indications, and expects full-year revenues between $38.2 billion and $39.4 billion. Free cash flow nearly doubled to $3.5 billion, reflecting robust business performance and efficient capital management.
Amgen, a biopharmaceutical company, suffered a data breach in July 2026 where unauthorized access to cloud-stored data led to the theft of patient protected health information and proprietary company data. The breach was disclosed in late July and ma...
Amgen is set to report its Q2 2026 earnings with analysts forecasting a 2.9% increase in revenue to about $9.45 billion, despite a projected 7% drop in earnings to $5.60 per share. The company benefits from strong sales of key drugs like Repatha, Tez...
U.S. markets ended last week higher as the Federal Reserve held interest rates steady, despite some dissent. This week features key economic data including Friday's July jobs report and manufacturing activity, alongside major earnings from SpaceX, AM...
